Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
5.00
+0.26 (5.49%)
At close: Oct 24, 2025, 4:00 PM EDT
4.750
-0.250 (-5.00%)
After-hours: Oct 24, 2025, 6:32 PM EDT
Exicure Revenue
In the year 2024, Exicure had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
31.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | -6,068.12% |
| Dec 31, 2021 | -483.00K | -17.10M | -102.91% |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
XCUR News
- 3 days ago - Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 20 days ago - Exicure Highlights Recent Achievements and Near-term Strategic Priorities - GlobeNewsWire
- 2 months ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 3 months ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 4 months ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire
- 5 months ago - Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
- 6 months ago - Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire